Nutri Advanced News

Research Shows Saccharomyces Boulardii Can Prevent & Reduce Diarrhoea

Research Shows Saccharomyces Boulardii Can Prevent & Reduce Diarrhoea

If you’ve ever taken antibiotics, worried about Traveller’s diarrhoea or struggle with IBS-related loose stools, then Saccharomyces boulardii could be a very useful probiotic for you…

What is Saccharomyces boulardii?
Saccharomyces boulardii is the only strain of yeast to have been formally recognised as a probiotic. S. boulardii works a bit differently to other probiotics though. It is a transient yeast, which means it doesn’t colonise the gut, but has its own (very) impressive list of health benefits:

✓ It has a sticky outer surface and can attach to a wide range of infectious micro-organisms, helping to eliminate them from the body.
✓ It produces natural anti-fungal agents such as caprylic acid and can help the body to eliminate harmful yeasts such as Candida albicans.
✓ It supports nutrient absorption, helps to prevent allergies and supports immune function.

S. boulardii’s best researched benefit however is as a natural agent to prevent or reduce many types of diarrhoea:

Traveller’s diarrhoea
S. boulardii is now strongly recommended for the prevention of traveller’s diarrhoea.
In terms of frequency and economic impact, traveller’s diarrhoea is the No.1 health problem for international travel; traveller’s diarrhoea is estimated to affect more than 60% of travellers to developing countries. Symptoms include vomiting, abdominal cramps, fever and diarrhoea; and while spontaneous recovery usually occurs after 4 days, some patients may have symptoms for weeks, and some go on to develop irritable bowel syndrome.

In a 2010 systematic review and meta-analysis of the evidence for the safety and efficacy of S. boulardii, scientific researchers concluded that:

S. boulardii can be strongly recommended for the prevention of antibiotic associated diarrhoea and traveller’s diarrhoea.”1

Antibiotic-associated diarrhoea
Overuse of antibiotics has become a significant global problem, and side effects such as diarrhoea are both problematic and incredibly common. S. boulardii is resistant to antibiotics and can be successfully used alongside antibiotics. The effectiveness of S. boulardii for the prevention of antibiotic side effects has been demonstrated in a number of human clinical trials and meta-analyses. In a study of 193 patients, administration of S. boulardii (1000 mg per day) from the beginning of antibiotic treatment and continued for 3 days after the course, significantly prevented the occurrence of diarrhoea compared to placebo.2 In another study of 338 patients taking antibiotics, S. boulardii (200 mg per day) significantly reduced the incidence of diarrhoea compared to placebo.3

IBS-associated diarrhoea
S. boulardii is also widely used to improve stool consistency in IBS patients with symptoms of diarrhoea. In a double-blind, placebo-controlled study in 34 patients with diarrhoea-predominant IBS, treatment with S. boulardii was found to decrease the daily number of stools and improved their consistency after 1 month of treatment.4

Saccharomyces boulardii – A proven, highly effective, natural support
Research into the beneficial effects of Saccharomyces boulardii continues to propel forward at an exciting rate. For many people struggling with, or worrying about the uncomfortable and often distressing symptoms of diarrhoea that can quickly ruin a holiday or affect everyday quality of life, S. boulardii offers simple, natural, relatively inexpensive and highly effective support. And with a proven safety profile, it’s certainly worth a try.

References:
1. Mcfarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010 May 14; 16(18): 2202-2222
2. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981–8.
3. Adam P. Essais cliniques controle´s en double insu de l’ultra-levure lyophilise´e (e´tude multicentrique par 25 me´decins de 388 cas). Me´d Chir Dig 1976; 5: 401–6.
4. Maupas, J., Champemont, P., and Delforge, M. (1983). Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double-blind, placebo-controlled-study. Med Chir Dig 12, 77-79.